Metabolic control in patients with non-proliferative diabetic retinopathy (NPDR) treated with anti-VEGF active injections or sham injections. Prespecified results from the Phase 3 GLOW1 Study in patients treated with tarcocimab tedromer.
By
1200 Page Mill Road Palo Alto, CA 94304 United States of America